Aviragen says its trial of asthma treatment vapendavir has failed to meet its primary endpoint.
Showing 25 of 1334
Pharmaceutical group Allergan has announced the acquisition of Zeltiq Aesthetics for $2.475bn to gain access to its body contouring technology.
"The preliminary findings suggesting the potential triglyceride-lowering activity of VK2809 in GSD Ia are encouraging," said Professor Dwight Koeberl of Duke University School of Medicine.
The FTSE 100-listed firm posted trading profits of US$1.020bn for 2016, down 7% from 2015’s US$1.099bn, on revenue 1% higher at US$4.67bn.
Pressure BioSciences shares advanced by 6% on Thursday after the company said it had achieved CE Marking for the Barocycler 2320EXTREME, the company's recently-released, next-generation PCT-based sample preparation instrument, and has the green light to sell in Europe
The medical products firm saw its earnings rise by 19% to US$243mln, or 44 US cents a share, up from US$205mln, or 37 US cents a share at the same stage a year earlier.
The drug developer will design a trial aimed at evaluating the superiority of ridinilazole over the current standard of care C. diff treatment
Cellmid recorded a 79% increase in hair loss product sales.
Incyte is interested in Calithera's technology that stmulates the immune system to combat cancer
AbbVie Inc shares were lower on Friday after the pharma reported quarterly adjusted revenue that missed analysts' estimates as weaker-than-expected sales of its hepatitis C treatment and cancer therapy overshadowed strong US demand for its flagship drug, Humira
J&J is paying $280 a share in cash for Actelion, retaining the Swiss firm's commercially available treatments for rare diseases such as pulmonary arterial hypertension.
At the moment, the healthcare firm M Pharma is a work in progress
Enrollment is continuing in the study with top-line data expected in mid-2017
“Funds raised in November provide capital to take the company towards profitability and we continue to invest in the pipeline, manufacturing and commercial platforms,” CEO JIm Phillips.
It completed its long-mooted listing on Nasdaq where, some would argue, pharmaceutical companies (and how to value them) are better understood.
The company will use an exclusive license it is acquiring for a new paraben-free technology for the task.
The firm purchased topical products for the relief of diabetic neuropathy symptoms via its earlier acquisition of Cincinatti-based 40Js.
The money will be used to pay down some of its US$30mln debt
District Judge Sue Robinson in Delaware announced a ban on Regeneron and Sanofi from selling their cholesterol drug, Praluent on the grounds of patent infringement.
The strategy will reduce development costs and open up multiple marketing avenues addressing different market segments.
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.
"Jasmine's depth of experience in driving corporate IP strategies and business development, as well as bringing products to market in Asia, will be a huge asset to Volition," said CEO Cameron Reynolds.
Dr H Lee Sweeney, who led the research, said: "There remains a large unmet need in Duchenne for therapies that can treat all affected boys and slow disease progression.
Vocera solutions provide hands-free voice communication, secure text messaging, patient engagement tools, and integrated clinical work flow